KEYMED BIOSCIENCES -0001 (64Z F) stock market data APIs

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodularis, and respiratory related indications. The company is also developing CMG901, a Claudin 18.2 antibody drug conjugate in Phase III trial to treat gastric and solid tumors; CM326, a recombinant humanized monoclonal antibody in Phase II trial for the treatment of CRSwNP and asthma; CM313, a humanized monoclonal antibody that targets CD38 in Phase I/II clinical study to treat systemic lupus erythematosus, primary immune thrombocytopenia, and IgA nephropathy; and CM355, a CD20 x CD3 bispecific antibody in Phase I/II clinical trial for the treatment of lymphoma. In addition, it develops CM383, a humanized monoclonal antibody in Phase 1 trial to treat Alzheimer's Disease; CM512, which is in Phase I clinical study for the treatment of moderate-to-severe AD, asthma, and chronic obstructive pulmonary disease; CM336, a BCMA x CD3 bispecific antibody in Phase 1 trial to treat relapsed or refractory multiple myeloma (RRMM); CM350, a GPC3 x CD3 bispecific antibody in Phase 1 trial for the treatment of solid tumors; CM369, an anti-C-C motif chemokine receptor 8 monoclonal antibody in Phase 1 trial to treat tumors; CM518D1, an antibody drug conjugate in IND trial for the treatment of solid tumors; and CM380, a GPRC5D x CD3 bispecific antibody in IND trial to treat RRMM. The company has a license agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.